VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
6am 10/16- shivering, 103 degree temperature, nausea, headache. 10/17- vomiting, extreme chest pain, shortness of breath, high heart rate, 104.8 temperature. Taken to a local hospital. Diagnosed with post covid 19 vaccination myocarditis with decreased cardiac function and elevated troponin which peaked at 573. Hospitalization inpatient cardiology floor at the hospital 10/18-10/10/21. Discharged with troponin levels at 170 and follow up echo and cardiology 10/28/21
|Vaccine Type||Manufacturer||Vaccine Name||Dose||Route||Site||Lot|
|RECVDATE:||21 October 2021|
|LAB_DATA:||High sensitivity troponin every 6-12 hours 10/18-10/21 Echocardiogram 10/18, 10/20 Ekg 10-18 Chest x-ray 10-18 CBC with differential 10/18, 10/21 Renal function panel 10/21 Magnesium 10/21 Red blood cell morphology 10/21 Westergren sedimentation rate 10/18 Respiratory virus panel 10/18 Covid-19 test 10/18 C-reactive protein 10/18 Brain natriuretic peptide 10/18|
|HISTORY:||Asthma, allergies, eczema|
|TODAYS_DATE:||21 October 2021|
|ALLERGIES:||cats, dogs, trees, grass, allergy to cold temperature|